# Regen BioPharma Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Regen BioPharma Inc). ## Overview Regen BioPharma Inc is a U.S.-based biopharmaceutical development company organized in Nevada and operating through its wholly owned subsidiary KCL Therapeutics, Inc. The company focuses on regenerative medical applications and early-stage drug candidates, including small molecules aimed at NR2F6 for oncology and autoimmune disease research. ## Products & services • Early-stage regenerative medical applications • NR2F6-targeting small molecule programs • Oncology immuno-activation candidates • Autoimmune disease immuno-suppression candidates • Licensing or sale of developed therapeutic assets - **Regenerative medical applications** (40%) — Development-stage therapeutic applications intended for later-stage licensing or advancement. - **Oncology programs** (30%) — Small-molecule and immune-activation candidates aimed at cancer applications. - **Autoimmune disease programs** (20%) — Immune-cell suppression candidates designed for autoimmune indications. - **Licensing and asset monetization** (10%) — Out-licensing or sale of developed applications after early clinical milestones. - Early-stage regenerative medical applications - NR2F6-targeting small molecule programs - Oncology immuno-activation candidates - Autoimmune disease immuno-suppression candidates - Licensing or sale of developed therapeutic assets ## Customers Regen BioPharma does not appear to sell commercial products to a broad end-customer base; instead, its economic counterparties are typically potential licensees, strategic partners, and acquirers of drug candidates. In practice, the company’s “customers” are pharmaceutical or biotechnology organizations that may acquire rights to programs after preclinical or early clinical development. It also relies on capital providers and related-party funding to support development activities. - **Pharmaceutical and biotechnology licensees** (primary) — Buy rights to early-stage therapeutic programs after proof-of-concept or early clinical work. - **Strategic acquirers** (primary) — Acquire developed applications or pipeline assets to add to their own portfolios. - **Research collaborators** (secondary) — Support discovery and development work around NR2F6 and related immune pathways. - **Financing counterparties** (primary) — Provide debt or equity funding that enables ongoing development and corporate operations. - Pharma and biotech licensees seeking early-stage assets - Potential acquirers of clinical-stage therapeutic programs - Research and development partners for drug development - Capital providers funding development and operations - Related parties providing notes and other financing ## Geography Regen BioPharma is headquartered in the United States and is organized under Nevada law, with office operations referenced in California. Its business is primarily U.S.-based, and the available disclosures do not indicate meaningful international revenue concentration. Geography matters mainly through U.S. regulatory oversight, clinical development requirements, and access to domestic capital markets. - United States is the core operating and corporate base - Nevada is the state of incorporation - California office space is used for administrative operations - Clinical and regulatory activity is tied to U.S. FDA oversight - No country-level revenue disclosure was provided ## Strategy The company’s strategy is to identify and develop regenerative and immunology-related therapeutic candidates through early clinical milestones, then monetize them through licensing or sale. This model reduces the need to build a full commercial infrastructure, but it depends on successful scientific validation, regulatory progress, and partner interest. The company also seeks external financing to fund development until assets can be advanced or monetized. - **Advance NR2F6-focused programs** (medium-term) — Clinical and scientific validation is needed before any licensing or sale value can be realized. - **Monetize assets through partnering** (medium-term) — Licensing or sale can convert development work into value without building a commercial sales force. - **Maintain access to financing** (short-term) — Development-stage biotech requires ongoing capital before product revenue is available. - Advance early-stage therapeutic candidates to proof-of-concept - Target NR2F6 biology for oncology and autoimmune applications - License or sell assets after Phase I/II milestones - Use a capital-light development model versus full commercialization - Secure external financing to fund research and development ## Risks Regen BioPharma faces the typical risks of an early-stage biotech company: clinical failure, regulatory delay, and uncertainty that any candidate will reach commercialization or attract a partner. The company also has going-concern and financing risk because it depends on external capital and related-party support to continue operations. As a development-stage issuer, its reported results can be highly sensitive to small changes in financing, legal structure, and accounting estimates. - **Clinical and regulatory failure** [high] — Therapeutic candidates are early-stage and must clear preclinical and FDA hurdles before value can be realized. - **Going-concern and liquidity risk** [critical] — The company states it may need additional equity or debt financing to support working capital and operations. - **Partnering and monetization risk** [high] — The business model depends on finding buyers or licensees for early-stage assets after development milestones. - **Related-party concentration** [medium] — Funding and facilities are tied to the CEO and related entities, increasing dependence on a small group of counterparties. - Clinical development may fail before proof-of-concept or approval - FDA approval is required before any product can be marketed - External financing may be unavailable or dilutive - Going-concern uncertainty reflects dependence on future funding - Related-party funding creates concentration and governance risk ## Accounting As a development-stage biotech, the company’s reported results are shaped by estimates around going concern, financing instruments, and related-party transactions rather than product revenue recognition. Convertible notes, notes payable, and equity issuances can materially affect the balance sheet and equity accounts, while R&D spending is expensed as incurred. Investors should also watch for any future impairment or valuation issues if acquired development assets or intangibles are recognized. - **Going concern** — Affects asset/liability classification and investor assessment of solvency - **Convertible notes and debt conversions** — Can create noncash financing items and dilution - **Related-party transactions** — Important for transparency, valuation, and governance analysis - **Research and development expense recognition** — Drives reported losses before any product revenue exists - Going-concern assessment is central to financial statement interpretation - Convertible notes and debt conversions affect liabilities and equity - Related-party notes and financing require close disclosure review - R&D is expensed as incurred, shaping operating loss timing - Future asset valuation or impairment could affect reported results --- *Last updated: 2026-04-29T04:53:11.133041+00:00*